기관지염 치료 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Bronchitis Treatment Market was valued at USD 6.9 billion in 2024 and is estimated to grow at a CAGR of 5.6% to reach USD 11.8 billion by 2034. This growth is being driven by an increasing burden of respiratory conditions, mainly due to smoking, exposure to environmental pollutants, occupational hazards, and recurring viral infections. Acute bronchitis, typically linked with seasonal viruses like influenza and RSV, is becoming more frequent, especially during colder months. This rise in respiratory illnesses is pushing up demand for effective bronchitis therapies, leading to stronger market performance and innovation in treatment modalities worldwide.

An aging global population is significantly boosting demand for bronchitis-related medications and therapies. Older adults are more likely to develop chronic respiratory conditions because of weakened immunity and diminished lung function. As the demographic aged 65 and over continues to expand, so does the consumption of bronchodilators, anti-inflammatory drugs, and other inhaled treatments. Bronchitis, defined as inflammation of the bronchial tubes, is typically treated by relieving airway inflammation, loosening mucus, calming cough, and improving breathing capacity. Most patients require drug-based therapies like bronchodilators, expectorants, and anti-inflammatories. In more severe cases, oxygen therapy is introduced to help patients manage their breathing effectively.

In 2024, chronic bronchitis segment generated USD 4.3 billion. This segment continues to grow due to the persistent and long-term nature of chronic bronchitis, which requires consistent medical supervision and complex therapeutic strategies. Unlike the short-lived nature of acute bronchitis, chronic bronchitis demands ongoing management and frequently overlaps with conditions such as chronic obstructive pulmonary disease (COPD), further escalating the need for continuous care. As older populations rise globally, cases of long-term respiratory disease are also on the rise, driving additional demand for chronic bronchitis treatment.

The medication segment held a commanding 79.3% share in 2024. This category includes widely used drugs such as bronchodilators, cough suppressants, mucoactive agents, and other therapeutic drugs. These treatments are essential for managing both acute and chronic bronchitis symptoms. Cough suppressants and expectorants are prescribed frequently to manage persistent coughing and help expel excess mucus from the airways-two of the most common and discomforting symptoms for bronchitis patients. The segment continues to thrive due to its proven effectiveness in symptom control and ongoing innovations in drug delivery systems, including long-acting formulations and inhalable formats, which improve patient adherence and therapeutic outcomes.

United States Bronchitis Treatment Market reached USD 2.3 billion in 2024, making it a key contributor to global growth. The increasing susceptibility of the population to respiratory illnesses is a primary growth driver. With more people exposed to allergens and pollution in dense urban areas, the number of bronchitis diagnoses continues to climb. Additionally, the country benefits from strong healthcare infrastructure, wider insurance coverage, and enhanced public health campaigns, all of which improve access to treatment. A well-established pharmaceutical presence, along with continual product development, is further solidifying the US market's position in the global bronchitis treatment landscape.

Major players in the Global Bronchitis Treatment Market include Sunovion Pharma, Glenmark, Lupin, 3M Pharmaceuticals, Pfizer, Sanofi, Reckitt Benckiser, Dr. Reddy's Laboratories, Boehringer Ingelheim, Johnson & Johnson, Teva Pharmaceuticals, GlaxoSmithKline, Aurobindo Pharma, Macleods Pharmaceuticals, and Merck. Companies operating in the bronchitis treatment market are adopting a multi-pronged approach to enhance market presence. Key players are heavily investing in R&D to develop extended-release formulations, inhalable therapies, and drug combinations that improve patient outcomes and compliance. Strategic partnerships and licensing agreements are being pursued to expand product pipelines and geographic reach. Many firms are increasing their focus on chronic bronchitis solutions, given the growing elderly population.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Disease type
  • 2.2.3 Treatment
  • 2.2.4 Age group
  • 2.2.5 End use
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Value addition at each stage
  • 3.1.3 Factors affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increased health access
    • 3.2.1.2 Increasing prevalence of respiratory diseases
    • 3.2.1.3 Advancement in drug developments and treatment options
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Drug compliance issues
    • 3.2.2.2 Availability of alternative medicines
  • 3.2.3 Market opportunities
    • 3.2.3.1 Increase in air pollution and smoking rates
    • 3.2.3.2 Expanding over-the-counter availability and increasing trend of self-medications
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Future market trends
• 3.6 Pipeline analysis
• 3.7 Pricing analysis
• 3.8 Consumer behaviour analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers and acquisitions
  • 4.6.2 Partnership and collaborations
  • 4.6.3 New product launches

Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Acute bronchitis
• 5.3 Chronic bronchitis

Chapter 6 Market Estimates and Forecast, By Treatment, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Medication
  • 6.2.1 By drug type
    • 6.2.1.1 Cough suppressants
    • 6.2.1.2 Bronchodilators
    • 6.2.1.3 Mucoactive agents
    • 6.2.1.4 Other drugs
  • 6.2.2 By type
    • 6.2.2.1 Prescription
    • 6.2.2.2 Over-the-counter (OTC)
  • 6.2.3 By route of administration
    • 6.2.3.1 Oral
    • 6.2.3.2 Nasal
    • 6.2.3.3 Injectable
• 6.3 Oxygen therapy

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Pediatric
• 7.3 Adult
• 7.4 Geriatric

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Clinics
• 8.4 Homecare settings
• 8.5 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 3M pharmaceuticals
• 10.2 Aurobindo Pharma
• 10.3 Boehringer Ingelheim
• 10.4 Dr. Reddy’s Laboratories
• 10.5 GlaxoSmithKline
• 10.6 Glenmark
• 10.7 Johnson & Johnson
• 10.8 Lupin
• 10.9 Merck
• 10.10 Macleods Pharmaceuticals
• 10.11 Pfizer
• 10.12 Reckitt Benckiser
• 10.13 Sunovion Pharma
• 10.14 Sanofi
• 10.15 Teva Pharmaceuticals